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Summary 
x Heterogeneity in TB burden is driven by the organism, host, environment and distal determinants. 
x More reliable data are needed, given inconsistent case ascertainment. 
x Targeting high-risk groups is an important consideration in designing interventions, but raises equity 
and efficiency issues. 
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Abstract 
Although less well-recognised than for other infectious diseases, heterogeneity is a defining feature 
of TB epidemiology. To advance toward TB elimination, this heterogeneity must be better 
understood and addressed. Drivers of heterogeneity in TB epidemiology act at the level of the 
infectious host, organism, susceptible host, environment and distal determinants. These effects may 
be amplified by social mixing patterns, while the variable latent period between infection and 
disease may mask heterogeneity in transmission. Reliance on notified cases may lead to 
misidentification of the most affected groups, as case detection is often poorest where prevalence is 
highest. Assuming average rates apply across diverse groups and ignoring the effects of cohort 
selection may result in misunderstanding of the epidemic and the anticipated effects of control 
measures. Given this substantial heterogeneity, interventions targeting high-risk groups based on 
location, social determinants or comorbidities could improve efficiency, but raise ethical and equity 
considerations. 
Key words 
tuberculosis, heterogeneity, epidemiology, case detection, interventions 
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Introduction 
Although estimates of the global burden of tuberculosis (TB) suggest gradual decline, this aggregate 
ƉƌŽĨŝůĞŵĂƐŬƐĂƉĂƚĐŚǇ ?ŚĞƚĞƌŽŐĞŶĞŽƵƐĞƉŝĚĞŵŝĐƚŚĂƚƉƌĞĚŽŵŝŶĂŶƚůǇĂĨĨůŝĐƚƐƐŽĐŝĞƚǇ ?ƐŵŽƐƚ
marginalised groups. Meanwhile, the causative organism ŝƐŶŽǁƚŚĞǁŽƌůĚ ?ƐůĞĂĚŝŶŐŝŶĨĞĐtious killer 
and dramatic reductions in burden will be necessary if the bold new End TB Targets are to be 
realised.[1] Heterogeneity in disease distribution increases as the burden of an infectious disease 
declines and becomes more unevenly distributed across space or social networks[2]  ? a 
phenomenon which is well recognised in the case of diseases such as malaria.[3] There are many 
reasons to suspect that TB epidemics are highly heterogeneous, such as the prominence of highly 
localised or household transmission, the wide geographical variation in disease burden within and 
between countries and the many individual-level factors strongly associated with risk of disease. 
Here we describe key drivers of heterogeneity in TB burden, discuss the challenges in quantifying 
this heterogeneity and consider implications for transmission dynamics and the design of 
interventions. 
Drivers of Heterogeneity 
Risk of infectious disease is dependent on characteristics of the infectious host, the organism, the 
susceptible host and the environment (Figure 1, Table). The complex interplay between the 
ƉĂƚŚŽŐĞŶĂŶĚƚŚĞŚŽƐƚ ?ƐŝŵŵƵŶĞƐǇƐƚĞŵĂŶĚthe propensity for Mycobacterium tuberculosis (Mtb) 
to enter a latent state following infection mean that many exposed individuals will never progress to 
active TB disease. Therefore, individual characteristics that predispose to susceptibility to infection, 
progression to disease after infection and infectiousness during disease episodes all contribute to 
heterogeneity, although the risk factors associated with each differ considerably. For example, risk 
of exposure is driven by sociodemographic factors (e.g. crowding, contact patterns), susceptibility to 
infection once exposed is influenced by processes that impair local immune responses (e.g. 
smoking), progression to disease may reflect systemic immune status (e.g. HIV, nutrition) and 
likelihood of onward transmission may be altered by cough symptomatology and disease duration 
(e.g. through access to care). 
The Infectious Host 
Medical and demographic factors also strongly influence the extent to which each affected person 
propagates Mtb infection. Smear-positive adults and particularly those with cavitary pulmonary 
tuberculosis transmit infection more extensively,[4] while many others, such as those with only 
extrapulmonary involvement, may infect no-one. Although children and persons with HIV are less 
likely to transmit, the degree of infectiousness is variable, with children aged over ten more often 
manifesting adult forms of TB.[5,6] Despite its limitations, smear microscopy remains the mainstay 
of TB diagnosis worldwide with advantages that include its ability to identify highly infectious 
individuals. Social factors such as mixing patterns also influence spread by modifying the number of 
contacts exposed and these patterns also differ by setting (e.g. household, workplace, general 
community). Importantly, social mixing patterns may act differently for Mtb than for other 
infections, given that Mtb, unlike many other major pathogens, is airborne and so can be 
transmitted without the need for direct person-to-person contact. However, the rate of transmission 
per day infectious is considerably lower than for other respiratory pathogens (e.g. measles, 
influenza),[7] meaning that amplifying factors such as cough characteristics, ability to generate 
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aerosols of appropriate size[8] and environmental factors may strongly influence whether infection 
occurs. Finally, myriad programmatic and social factors delay diagnosis and so prolong the infectious 
period and increase the duration of exposure,[9] thereby potentiating heterogeneity through their 
impact on the most marginalised groups.  
The Infecting Organism 
Mtb is a clonal pathogen that displays variable fitness and a complex interaction with its human 
host.[10] Its multiple lineages differ in their genomic make-up and in several aspects of their clinical 
and epidemiological behaviour, including disease progression, disease severity, transmissibility and 
geographic distribution (Supplemental bibliography). With recent advances in molecular 
epidemiology, the influence of Mtb genetic diversity on the outcomes of TB infection and disease is 
increasingly recognised. Strains are thought to have adapted to the human population they 
affect,[11] resulting in a sympatric relationship whereby co-evolved host populations show high 
rates of TB due to certain strains, but concentration within high-risk groups elsewhere.[12] However, 
the discordance in findings between settings and the complex interaction between pathogen, host 
and environment remain challenges to understanding these processes.  
Arguably, the most critical form of pathogen-related heterogeneity is drug resistance, which makes 
clinical management considerably more challenging and expensive. Epidemiologically, transmission 
cycles of drug-resistant TB (DR-TB) differ from those of drug-susceptible TB because of limited access 
to the diagnostics available for determining drug resistance, the long duration of DR-TB treatment 
and clustering of DR-TB patients in high-risk settings. All these factors may act to prolong the 
infectious period, sustaining transmission chains of DR-TB.[13] Resistance-conferring mutations may 
be offset by associated physiological impairments in the organism which limit its ability to survive 
ĂŶĚƌĞƉƌŽĚƵĐĞ ? “fiƚŶĞƐƐĐŽƐƚƐ ? ?, although sustained drug exposure may select for bacteria with 
compensatory mutations.[14] Moreover, fitness costs are likely to vary according to the drug in 
question (e.g. higher for rifampicin resistance than for isoniazid or streptomycin),[15] while both 
modelling studies and large-scale outbreaks highlight the potential for DR-TB to proliferate.[16] 
The Susceptible Host 
Characteristics of the susceptible host also markedly influence the likelihood of disease following 
exposure, which may reflect both susceptibility to infection or greater risk of progression to disease 
for those infected. Patterns of reactivation differ markedly by age, and comorbidities such as HIV, 
diabetes, malnutrition and heavy alcohol are critical considerations in the variation of risk of disease 
progression observed (Supplemental bibliography). For example, HIV is the strongest individual-level 
risk factor and a major driver of the TB epidemic in many parts of Africa, while the rising global 
prevalence of non-communicable diseases (e.g. diabetes) may hinder our ability to achieve control 
targets by impairing host immunity at the population level.[17] History of exposure and disease are 
also important, as people who are latently infected likely have partial protection against reinfection 
with the pathogen,[18] whereas previously treated persons are likely to be at substantially increased 
risk for recurrent disease.[19] This latter increase in risk may reflect repeated exposure, incomplete 
treatment, or underlying immunological vulnerability.[20] 
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The Physical Environment 
The setting in which TB is transmitted is also an important modifier of spread  ? either due to 
increased population density, congregation of individuals with higher rates of specific risk factors or 
directly through environmental features that facilitate airborne transmission. Characteristics of the 
physical environment that may contribute to transmission include crowding, poor ventilation and 
high levels of indoor air pollution.[21] Furthermore, locations with these characteristics (e.g. clinics, 
public transit, churches, prisons, mines and informal drinking spaces) are often frequented by the 
same high-risk individuals, further fuelling heterogeneous transmission in these sites. These 
locations are themselves likely to be in close proximity, enhancing transmission in impoverished 
areas[22] and sustaining the epidemic.[23] 
Structural and Social Determinants 
Heterogeneity at the community level is driven by a complex network of proximal and distal 
determinants that may not always be fully explained by quantifiable risk factors. Migration, 
urbanisation, demographic transition and other broad global trends combined with weak and 
inequitable policy and planning lead to pockets of poverty, unhealthy behaviours and weak health 
systems in which TB thrives.[24] Social or spatial clustering of the individual-level characteristics 
described in the preceding sections may magnify the effect of these risk factors through 
transmission, as persons contact one another more if they share similar characteristics (assortative 
mixing). However, understanding of the effect of the various upstream determinants responsible for 
driving heterogeneity in TB burden is limited by the relative paucity of modelling studies in this 
area.[25] 
Challenges in Quantifying Heterogeneity 
Although substantial between- and within-country differences in burden are frequently reported, 
challenges exist in interpreting the differences observed between demographic, geographical or 
other subdivisions of the population. Our understanding of the population-level epidemiology of TB 
disease relies to a large extent on cases that have sought care, received a diagnosis, and been 
recorded through surveillance systems or local studies. The substantial proportion of cases that does 
not reach this stage in many settings[1] means that our estimates of heterogeneity in burden are 
prone to bias (Figure 2, Panels A and B). A particular consequence of relying on data from detected 
cases arises from the negative correlation between TB burden and access to care, which may mask 
heterogeneity in disease. For example, TB prevalence surveys consistently show a male 
predominance among adult TB cases, but this gender gap is much smaller in notifications  ? 
suggesting that men experience a higher burden but seek or access care at a lower rate than 
women.[26] Similar and even stronger unobserved effects  ? whereby mechanisms that increase risk 
of TB also decrease the probability of detection  ? may exist for features such as socio-economic 
status or locality. Moreover, even if bias could be eliminated from health information systems, 
routinely collected data are not typically disaggregated beyond broad age categories, geographic 
regions and drug resistance profiles, thereby limiting our ability to observe heterogeneity between 
smaller sub-populations without specifically designed studies. 
Much less biased measures of disease burden are available from the recent increase in TB 
prevalence surveys. However, prevalence surveys in the general population are expensive 
undertakings and typically designed to yield a relative precision of 20% to 25%,[27] limiting their 
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ability to discern patterns among subgroups or at the district/local level. Moreover, prevalence 
surveys are by design cross-sectional, meaning that they cannot provide information on 
heterogeneity through time without additional assumptions or repeated data collection. 
One important consequence of detection bias is that clusters of notifications are difficult to 
interpret. Apparent hotspots of TB disease may represent either true areas of intense transmission 
or better diagnosis (via targeted campaigns or differential access to care), such that the areas of 
most intense transmission may be those with the highest notification rates in some settings and the 
lowest in others. Travel to access care may further exaggerate this process, creating artefactual 
aggregations of notifications. By contrast, heterogeneity in transmission may be masked by the often 
substantial latent period between infection and disease onset, during which infected individuals may 
relocate (Figure 2, Panels C and D). This process smooths disease distribution and obscures 
transmission chains, while the distribution of transmission and latent infection are even harder to 
observe in an era when population-wide surveys of infection are no longer undertaken. 
Implications for Understanding and Modelling Transmission 
The impact of heterogeneity of infectiousness is influenced by characteristics of the infectious host 
and the organism being transmitted, and can be explored through its specific effects on the basic 
reproduction number, R0.[28] While the point estimate of R0 is often emphasised as a measure of 
the expected number of secondary cases caused by an average index case in an infection-naïve 
population, infectiousness may more appropriately be viewed as a probability distribution across a 
population of individuals, each with their own expected number of secondary cases. While 
superspreading is clearly observable in TB genomic studies,[29] saturation of close contacts  ? 
whereby contacts occur primarily among individuals who have already been infected  ? may increase 
the importance of community transmission in high-burden settings.[30] 
When heterogeneity in susceptibility to TB exists, concerns regarding the assumption of a 
homogeneous population parallel concepts familiar in non-communicable diseases, such as cohort 
selection and frailty models in survival analysis. As higher-risk individuals develop incident 
disease,[19,31] the incidence rate of a cohort may decline simply because those who remain 
susceptible have a lower average risk (Figure 2, Panels E and F). This process is disabled in models 
that collapse risk distributions to their mean values, leading to inaccurate simulations and biased 
predictions. Population-level heterogeneity in susceptibility can also induce thresholds near which 
small epidemiological changes will cause dramatic shifts in disease burden, leading to unanticipated 
effects of preventive interventions[32] and faster emergence of drug-resistant strains.[33] 
Any transition rate can be affected by cohort selection, as illustrated in Figure 3. Instead of the 
disease incidence process discussed above, consider a cohort of individuals with active TB comprised 
of two groups: fast and slow care seekers. As the faster care seekers leave the cohort earlier, the 
overall care-seeking rate will decline over time, even though it remains constant in each group. This 
process complicates estimation procedures and can be especially problematic in relation to rates of 
infection, which are proportional to the prevalence of infectious individuals and so part of a 
feedback loop. Moreover, epidemiological uncertainty around the most appropriate parameter 
values for transmission models means that multiple parameter sets may superficially replicate 
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observed burden,[34] which is particularly problematic for an endemic infection with a prolonged 
and unpredictable latency period. 
Implications for Control 
Targeting Risk Groups 
A consequence of the heterogeneity in transmission, infection, incidence and mortality is that 
benefits of interventions will differ depending on the groups targeted and the distribution of the risk 
factors introduced above. This consideration motivates much current TB policy, with groups at 
higher risk of infection, disease or poor outcomes from TB episodes, such as household contacts, 
children, persons living with HIV, individuals with end-stage renal disease and previously treated 
people identified as high-priority groups for screening and treatment of latent and active TB 
(Supplemental bibliography). Heterogeneity in historical TB exposure is also a focus of interventions, 
with many low-incidence countries targeting services to foreign-born individuals,[35] given their 
higher LTBI prevalence and consequent risk of reactivation. However, interventions targeted at high-
risk populations have not always been successful: a trial of mass screening and preventive treatment 
in South African miners had no impact on TB rates,[36] because of reactivation of non-cured 
infections and reinfection in the context of insufficient treatment and ongoing high environmental 
transmission risk.[37] 
Synergies with non-  interventions 
Regular interactions with the health care system for the management of chronic and non-
communicable diseases offer the opportunity for intensified case finding efforts, given that many 
such conditions increase TB risk or co-occur in populations with such increased risk. More broadly, 
strengthening health systems for both TB and non-communicable disease control provides the 
potential for synergistic interventions across diseases,[38] while improving control by addressing 
distal determinants should also be a high priority.[39] The observation that both historical and more 
recent declines[24,40] in TB burden have usually been achieved in the context of improvements in 
socio-economic indicators highlights the importance of such upstream determinants and is 
particularly relevant in the Sustainable Development Goals era. 
ographical Targeting 
TB incidence shows considerable geographical clustering at multiple resolutions[41] and spatial 
targeting of interventions has the potential to achieve major reductions in burden through focusing 
on geographically discernible TB hotspots,[42] although the extent of mixing between hotspots and 
the broader population is important to quantify as it will modify the impact of such 
interventions.[43] Intensive TB control interventions targeted at Inuit communities in northern 
Canada, Alaska and Greenland were effective at substantially reducing the extreme rates of TB 
incidence and mortality observed in the 1950s.[44] New and emerging analytic tools offer 
opportunities to identify and quantify TB hotspots, such as a recent genomic analysis in Peru that 
highlighted the spatial aggregation of multidrug-resistant genotypes.[23] 
Effect of Interventions on Heterogeneity 
Where substantial reductions in TB burden are achieved, heterogeneity in TB distribution may 
increase, as transmission becomes more localised to remaining regions and population groups with 
fewer resources, limited healthcare access, and insufficient adherence to policy. However, even 
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when fully implemented, control efforts may increase or decrease transmission heterogeneity 
depending on the intervention design. Interventions directed at those with poor access to care and 
so high burden of disease may reduce heterogeneity, whereas interventions that strengthen routine 
programmatic management may increase heterogeneity even while decreasing overall burden. 
Heterogeneity may modify the impact of both targeted and untargeted interventions depending on 
the background burden of disease. For example, successful detection and treatment of a single 
active case may eliminate transmission from a community in a low-burden setting, whereas this 
would be harder to achieve in a high-burden setting. This may lead to unexpected relationships 
between control efforts and consequent reduction in the annual risk of Mtb infection.[45] 
Economic and Equity Concerns 
The targeting of TB control interventions to those with high rates of infection or disease is expected 
to increase the effectiveness of interventions. Consequent gains in efficiency will depend on 
coverage levels, accessibility, disease prevalence and contribution to transmission in the wider 
population of the target group. There are economies of scale to be achieved when increasing 
coverage, yet at high levels of coverage or for difficult to reach populations, targeted strategies may 
require additional supporting activities and so increase resource needs. For example, the cost-
effectiveness of active case finding strategies is driven by both the heterogeneity in disease rates 
and in the cost of reaching different subgroups.[46] While maximising impact within a given budget 
is a key objective in priority setting, heterogeneity in burden, health care access and financial 
resources are linked to equity concerns in resource allocation for TB control strategies. Conceptually, 
the difference between inequalities and inequities is a value judgement about whether the observed 
heterogeneity is considered fair. Policy makers should seek to ensure that populations already 
experiencing increases in risk due to socioeconomic or other conditions (e.g., crowding, 
incarceration) do not experience additional disparities in access to TB diagnosis and treatment, 
financial burden of illness, or unwarranted exposure to infection. While the reduction of such 
disparities is a key policy objective, there are situations in which achieving it may imply trade-offs in 
efficiency gains. For example, interventions aiming to place new technologies at decentralised 
locations may not be as cost-effective as placement at higher levels of the health system, yet may 
still be prioritised to reduce social inequities in financial burden, health outcomes and access to 
health services.[47] 
Ways Forward and Conclusions 
Causes of heterogeneity in TB epidemiology are diverse and include characteristics of the infectious 
host, pathogen, susceptible host, environment and distal determinants  ? factors which may interact 
to amplify or reduce heterogeneity. Observed heterogeneity may not reflect reality and targeted 
epidemiological studies to quantify disease burden in more detail would be valuable, e.g. prevalence 
surveys powered to obtain precise estimates of disease burden in specific population risk groups and 
age-groups. 
All TB modelling studies must judge which aspects of heterogeneity are sufficiently important to 
include given the question posed and the local context, and which should not be specifically 
incorporated for parsimony. This highlights the importance of: 1) detailed, context-specific data, 2) 
refining parameter estimation through epidemiological research, 3) communicating uncertainty in 
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predictive modelling and 4) confirmation of the predicted effectiveness and cost of interventions 
through operational research. 
Heterogeneity has implications for the effectiveness and efficiency of control interventions. 
Targeting of interventions is an appropriate consideration in designing intervention strategies, 
although evidence to support specific targeted approaches is sometimes weak or contradictory. 
Therefore, such strategies must be considered in the context of resource availability and the ethical 
imperative to ensure universal access to high-quality care. Moreover, it is also important to balance 
the need for clear guidelines that can facilitate the broad implementation of interventions at a 
national or global level against the importance of developing interventions that are targeted towards 
specific characteristics of regional or local epidemics. 
As the global TB control community looks towards ending TB, understanding and harnessing 
heterogeneity to improve control will become increasingly important. Key considerations in 
addressing heterogeneity include better assessment of disease burden in population subgroups, 
context-specific modelling, targeting of interventions and a focus on distal determinants of 
inequities in health status. 
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Figure 1 Conceptual framework for understanding heterogeneity in TB epidemiology 
The cone indicates that the most local drivers are positioned towards the top of the figure and the broadest drivers 
towards bottom, rather than reflecting the importance of these factors. 
Figure 2 Illustration of some selected concepts from the text 
Panel A illustrates the degree of heterogeneity that might be observed among individuals with good access to the 
healthcare system (unblurred discs) compared to those with poor access (blurred discs). This may be substantially less than 
the heterogeneity that exists in the population as a whole (Panel B). 
Panel C represents a series of transmission events and Panel D illustrates the subsequent relocation of infected and 
uninfected individuals. This results in a more homogeneous distribution of infection across the population at this later time 
point, even though transmission was highly heterogeneous. 
Panel E represents a series of individuals at variable risk of infection and Panel F illustrates selection of higher risk 
individuals through the infection process. Although infection is the selecting illustrated process here, similar principles 
would apply to progression from infection to disease, through stages of the disease process and to interaction with the 
health system. 
Figure 3. Composition of a simple two-stratum heterogeneous cohort over time from entry to an 
epidemiological state (active undiagnosed TB) 
Plot displays the percentage of patients with active tuberculosis remaining undiagnosed after the onset of infectiousness 
(time 0 on the horizontal axis), under the assumption that 50% of the initial cohort has an average duration of 
ŝŶĨĞĐƚŝŽƵƐŶĞƐƐŽĨŽŶĞŵŽŶƚŚ ? “ŚŝŐŚƌĂƚĞŐƌŽƵƉ ? ?ďůƵĞ), and 50% of the cohort has a duration of infectiousness of 6 months 
 ? “ůŽǁƌĂƚĞŐƌŽƵƉ ? ?ƌĞĚ ?. The true total percentage of patients remaining infectious with time since onset of 
infectiousness (solid line) is compared against: the proportion that would be expected to remain if the whole cohort was 
assumed to have the average time to diagnosis (3.5 months); and the proportion that would be expected to remain if the 
whole cohort was assumed to have a rate of diagnosis that is the average of the rates of the two groups (dotted line). The 
amount of the total population comprised of high-rate and low-rate persons at each time point is indicated by coloured 
shading, demonstrating that the remaining cohort is increasingly comprised of low-rate individuals over time.   
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  Main messages 
x Although often masked by reported aggregate estimates, the distribution of TB is 
heterogeneous and harnessing this heterogeneity may be critical to further 
progress in the fight against TB. 
x Drivers of heterogeneity in TB burden include characteristics of the organism, 
infectious host, susceptible host, environment and distal determinants. 
x More detailed epidemiological data are needed to define and quantify this 
variation. 
x Quantification of heterogeneity in TB distribution is complicated by 
heterogeneity in the process of detecting cases. 
x Incorporating heterogeneity in TB transmission models is necessary when 
capturing epidemiological phenomena that include superspreading and cohort 
selection. 
x Targeting high-risk groups is an established approach and is an important 
consideration in designing control interventions, but may not always improve 
effectiveness and may incur additional costs. However, targeting interventions 
should be considered in the context of ethical and equity concerns, 
programmatic efficiency and synergies across the broader health system. 
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Table. Examples of Specific Forms of Heterogeneity and W s Forward 
Source of 
Heterogeneity 
Examples of existing evidence Data needs Analytic needs Intervention needs 
The Infectious 
Host 
Sequencing and social network 
analysis suggest that some 
individuals may act as 
 “ƐƵƉĞƌƐƉƌĞĂĚĞƌƐ ?[48] 
Importance of biological 
variables, e.g. aerosolisation, 
cough frequency 
Implications of hosts with 
differential infectiousness and 
superspreading 
Tools to identify the most infectious 
patients 
 
 Available data on contact patterns 
(principally from low-burden 
settings) suggest age-specific 
(assortative) mixing 
Data on contact patterns 
from high-burden settings 
and for risk factors relevant 
to TB (e.g. HIV status) 
Importance of population groups to 
sustaining transmission relative to 
their burden of disease 
Case-finding efforts designed to identify 
patients with high-risk mixing patterns for 
broader dissemination of infection 
The Infecting 
Organism 
Strain responsible for extensive 
community spread confirmed to 
be highly virulent in mouse 
model[49] 
Mechanisms of strain 
diversity and virulence 
Implications of selecting for strains 
of greater fitness 
Interventions to limit infectiousness of 
difficult-to-treat strains 
 Highly resistant forms of TB 
causing extensive outbreaks, e.g. 
XDR-TB in Tugela Ferry, South 
Africa[50] 
Fitness costs associated with 
drug resistance 
Likely future trajectory of drug 
resistance 
Improved identification and treatment of 
highly transmissible strains of drug-
resistant tuberculosis 
The Susceptible 
Host 
Individuals previously treated for 
TB had higher rates of recurrent 
TB due to reinfection than the 
general population in Cape Town, 
South Africa[51] 
Protection or susceptibility 
afforded by past TB episodes 
and whether this is 
attributable to infection or 
progression risk 
Distinguish the individual-level 
effect of increased susceptibility 
post-disease episode from the 
effect of selecting for a more 
susceptible cohort through 
infection 
Protection of highest risk individuals from 
infection or progression to disease 
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 Specific risk groups may 
experience polyclonal 
outbreaks[52] 
Better estimates of disease 
prevalence in risk groups  
Anticipated effects of trends in 
comorbid risk factors on TB 
TB control interventions that link with 
systems for other high-risk conditions 
 
The Physical 
Environment 
Incarceration may have been a 
significant driver of community 
transmission [53] 
Better estimates of location-
specific TB transmission risk 
Valid models for translating 
environmental heterogeneity into 
transmission risk 
Active case-finding targeted at high-risk 
environments (e.g. prisons, transit) 
 Greater proportion of infected 
contacts in less well ventilated 
hospital wards[54] 
Ability of specific 
interventions (e.g. improved 
ventilation) to reduce that 
risk 
Projected population-level impact 
of targeted environmental 
interventions 
Mitigation of TB transmission through 
modification of high-risk built 
environments 
Distal 
Determinants 
Ecological observation of declining 
TB rates during times of 
improvements in living 
standards[40] 
Mechanistic linkages 
between poverty alleviation 
and TB transmission 
Projected ability of social 
protection and similar efforts to 
reduce heterogeneity 
Linkage between TB control programs 
and schemes to alleviate poverty and/or 
address other distal determinants 
 Association between coverage of 
ƌĂǌŝů ?ƐĐŽŶĚŝƚŝŽŶĂůĐĂƐŚƚƌĂŶƐĨĞƌ
program and improved TB 
control[55] 
TB-specific effects of broader 
interventions 
Models of the impact of TB on 
other outcomes in vulnerable 
populations 
Implementation of TB interventions in a 
fashion that mitigates burden on the 
highest risk populations, thus promoting 
equity and reducing disparities in risk 
XDR-TB, extensively drug-resistant tuberculosis.
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